One Trick Pony?29 Mar 2019 11:51
Good morning!
I've been doing some research into Motif ahead of an investment. On the face of it, the company looks like it has potential to deliver an excellent return to shareholders - so long as the FDA give approval for Iclaprim. However, what if they don't? Is there any supportive evidence that provides details about Motif's progress with the EMA? What stage are they with trials in Europe? Do we know if the MAA was submitted in Europe last year? Is there another route to get an NDA in the US if the FDA reject Iclaprim when they get together with Motif at the meeting?
I've been on their website and followed the path under "Development Programs" and it appears that Iclaprim is the only drug that is under development. Their 2017 annual report only mentions Iclaprim and nothing about future plans. Do they have anything else in their stable? Or, as my post title asks, are Motif just a One Trick Pony?
Hope you don't mind me asking - and if any of the above is available and published somewhere, I would be grateful if you wouldnt mind directing me to it.
Many thanks,